Education
About Us
Working with TipRanks
Follow Us
Fortress Biotech (FBIO)
NASDAQ:FBIO
FBIO Stock Chart & Stats
$2.59
>-$0.01(-0.47%)
At close: 4:00 PM EST
$2.59
>-$0.01(-0.47%)
Day’s Range― - ―
52-Week Range$1.33 - $4.20
Previous CloseN/A
Volume489.64K
Average Volume (3M)1.34M
Market Cap
$73.49M
Enterprise Value$43.77M
Total Cash (Recent Filing)$86.22M
Total Debt (Recent Filing)$68.29M
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Mar 26, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.11
Shares Outstanding29,754,753
10 Day Avg. Volume683,913
30 Day Avg. Volume1,343,678
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.86
Price to Sales (P/S)0.73
P/FCF Ratio-0.44
Enterprise Value/Market Cap0.60
Enterprise Value/Revenue0.70
Enterprise Value/Gross Profit1.07
Enterprise Value/Ebitda-1.13
Forecast
1Y Price Target
$10.75Price Target Upside315.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Drug ApprovalNo issues were raised regarding efficacy or approvability for the potentially transformative drug CUTX-101.
Financial PerformanceFortress benefits from its 68% ownership of Urica, gaining indirect equity ownership in Crystalys and future 3% royalty payments on dotinurad sales.
Revenue GrowthJourney's product Emrosi, which Fortress partially owns, has been approved for treating rosacea, representing a key revenue growth driver with potential peak sales in the hundreds of millions.
Bears Say
Fortress Biotech News
FBIO FAQ
What was Fortress Biotech’s price range in the past 12 months?
Fortress Biotech lowest stock price was $1.32 and its highest was $4.20 in the past 12 months.
What is Fortress Biotech’s market cap?
Fortress Biotech’s market cap is $73.49M.
When is Fortress Biotech’s upcoming earnings report date?
Fortress Biotech’s upcoming earnings report date is Mar 26, 2026 which is in 122 days.
How were Fortress Biotech’s earnings last quarter?
Fortress Biotech released its earnings results on Nov 14, 2025. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of -$0.42 by $0.53.
Is Fortress Biotech overvalued?
According to Wall Street analysts Fortress Biotech’s price is currently Undervalued.
Does Fortress Biotech pay dividends?
Fortress Biotech does not currently pay dividends.
What is Fortress Biotech’s EPS estimate?
Fortress Biotech’s EPS estimate is -0.35.
How many shares outstanding does Fortress Biotech have?
Fortress Biotech has 29,754,753 shares outstanding.
What happened to Fortress Biotech’s price movement after its last earnings report?
Fortress Biotech reported an EPS of $0.11 in its last earnings report, beating expectations of -$0.42. Following the earnings report the stock price went up 5.221%.
Which hedge fund is a major shareholder of Fortress Biotech?
Currently, no hedge funds are holding shares in FBIO
Fortress Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.75 (315.06% Upside)
$10.75 (315.06% Upside)
Crowd Wisdom
Very Positive
Last 7 Days >0.1%
Last 30 Days ▲ 4.6%
Last 30 Days ▲ 4.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
49.17%
12-Months-Change
Fundamentals
Return on Equity
10.35%
Trailing 12-Months
Asset Growth
9.75%
Trailing 12-Months
Company Description
Fortress Biotech
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing innovative drug candidates in the fields of oncology, immunology, and other therapeutic areas. The company operates through a diverse portfolio of subsidiaries and collaborations, aiming to bring novel therapies to market that address unmet medical needs. Fortress Biotech's core products include several proprietary drug candidates and partnerships with various biopharmaceutical companies to enhance its research and development efforts.
FBIO Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth driven by the successful launch of EMROSI, improved EBITDA, and expanding prescriber base. However, challenges remain with the decline in legacy product revenues and delays in health plan formulary adoption for EMROSI. Despite these issues, the company is optimistic about EMROSI's potential and future revenue growth.View all FBIO earnings summariesFBIO Stock 12 Month Forecast
Average Price Target
$10.75
▲(315.06% Upside)
Technical Analysis
Ownership Overview
4.20% Insiders
3.59% Mutual Funds
5.36% Other Institutional Investors
83.93% Public Companies and Individual Investors